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Background: Diabetes is characterized by profound lipid abnormalities. The objective of this study was to examine
changes in concentrations of lipids and apolipoprotein B among participants stratified by glycemic status (diabetes,
undiagnosed diabetes, prediabetes, and normoglycemia) in the United States from 1988–1991 to 2005–2008.
Methods: We used data from 3202 participants aged ≥20 years from the National Health and Nutrition
Examination Survey (NHANES) III (1988–1991) and 3949 participants aged ≥20 years from NHANES 2005–2008.
Results: Among participants of all four groups, unadjusted and adjusted mean concentrations of total cholesterol,
low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B, but not
triglycerides, decreased significantly. Among participants with prediabetes and normoglycemia, unadjusted and
adjusted mean concentrations of high-density lipoprotein cholesterol increased significantly. Adjusted mean
log-transformed concentrations of triglycerides decreased in adults with undiagnosed diabetes and prediabetes.
During 2005–2008, unadjusted concentrations of apolipoprotein B ≥80 mg/dl were observed in 72.8% of
participants with diagnosed diabetes, 87.9% of participants with undiagnosed diabetes, 86.6% of participants
with prediabetes, and 77.2% of participants with normoglycemia. The unadjusted use of cholesterol-lowering
medications rose rapidly, especially among participants with diabetes (from ~1% to ~49%, P <0.001). The use
of fenofibrate, gemfibrozil, and niacin rose significantly only among adults with diagnosed diabetes (from ~2%
to ~8%, P = 0.011).
Conclusion: Lipid profiles of adults with diabetes improved during the approximately 16-year study period.
Nevertheless, large percentages of adults continue to have elevated concentrations of apolipoprotein B.
Keywords: Apolipoprotein B, Cholesterol, Diabetes, High-density lipoprotein cholesterol, Lipids, Prediabetes,
Triglycerides, Fenofibrate, Gemfibrozil, Niacin* Correspondence: eford@cdc.gov
1Division of Population Health, National Center for Chronic Disease
Prevention and Health Promotion, Centers for Disease Control and
Prevention, Atlanta, GA, USA
Full list of author information is available at the end of the article
© 2013 Ford et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Ford et al. Cardiovascular Diabetology 2013, 12:26 Page 2 of 13
http://www.cardiab.com/content/12/1/26Background
During the last several decades, diabetes has emerged as
a major public health problem in the United States as
the incidence and prevalence of obesity has escalated
rapidly [1,2]. The lifetime probability of developing this
disease is approximately 32.8% for men and 38.5% for
women [3], and an estimated 25.6 million adults have
diabetes [4]. Furthermore, diabetes has an enormous im-
pact on health care costs in the United States; in 2007,
for example, the economic costs attributable to this con-
dition were estimated to have been $174 billion [4].
Much of the toll exacted by diabetes is due to the
complications of this disease, notably from cardiovascu-
lar disease: as many as 65% of people with diabetes will
die of cardiovascular disease, and diabetes approximately
doubles the risk of developing cardiovascular disease
[5,6]. This increased risk for cardiovascular morbidity
and mortality is largely a function of a number of cardio-
metabolic abnormalities, including lipid abnormalities.
In general, people with diabetes tend to have elevated
concentrations of triglycerides and apolipoprotein B, low
concentrations of high-density lipoprotein cholesterol,
and an elevated number of small dense low-density lipo-
protein cholesterol particles [7].
Previous trend studies have shown some improvement
in lipid abnormalities in adults with diabetes including
total cholesterol, low-density lipoprotein cholesterol, and
non-high-density lipoprotein cholesterol [8-10]. How-
ever, less is known about apolipoprotein B, which some
have argued is a superior marker of cardiovascular risk
than low-density lipoprotein cholesterol or non-high-
density lipoprotein cholesterol [11]. Consequently, the
objective of the present study was to examine changes in
concentrations of lipids with a focus on apolipoprotein B
among adults with diagnosed and undiagnosed diabetes
from 1988–1991 to 2005–2008. In addition, we examined
changes in concentrations of lipids and apolipoprotein B
among participants with prediabetes and normoglycemia.
Research design and methods
The analyses for the present study were conducted using
data from the first phase of the National Health and Nu-
trition Examination Survey (NHANES) III (1988–1991)
and from NHANES 2005–2008. Using a multistage,
stratified sampling design, participants were recruited
into the survey. After an interview in the home, partici-
pants were invited to attend one of three examination
sessions: morning, afternoon, or evening. Persons
attending the morning session were asked to fast over-
night. In the mobile examination center, participants
completed additional questionnaires, had a series of
examinations, and provided biological specimens includ-
ing blood. Interview and examination response rates
were 86% and 78%, respectively, for NHANES III, 80%and 77%, respectively, for NHANES 2005–2006, and
78% and 75%, respectively, for NHANES 2007–2008.
Details about the surveys and their methods have been
published previously [12,13].
Four groups of participants were defined: those with
diagnosed diabetes, those with undiagnosed diabetes,
those with prediabetes, and those with normoglycemia.
Participants with diagnosed diabetes were identified by
responses to the NHANES questions: “Have you ever
been told by a doctor that you have diabetes or sugar
diabetes?” or “Have you ever been told by a doctor or
health professional that you have diabetes or sugar dia-
betes?”, respectively, in the two surveys. Those who
responded “yes” were considered to have diagnosed dia-
betes. Participants who responded that they may have
had "borderline" diabetes or were "prediabetic" were
coded as not having diagnosed diabetes. Concentrations
of HbA1c were used to establish the glycemic status of
the remaining participants without diagnosed diabetes
as follows: undiagnosed diabetes: ≥6.5%; prediabetes:
5.7- < 6.5%; and normal: <5.7%.
High-performance liquid chromatography (HPLC) was
used to measure concentrations of HbA1c in NHANES
III (Bio-Rad DIAMAT glycosylated hemoglobin analyzer
system, Bio-Rad Laboratories, Hercules, CA) and
NHANES 2005–2008 (NHANES 2005–2006: Tosoh
A1c 2.2 Plus Glycohemoglobin Analyzer, Tosoh Medics,
Inc., So. San Francisco, CA; NHANES 2007–2008:
Tosoh G 7 HPLC Glycohemoglobin Analyzer, Tosoh
Medics, Inc., So. San Francisco, CA). Serum concentra-
tions of total cholesterol, high-density lipoprotein chol-
esterol, and triglycerides were measured enzymatically
on a Hitachi 704 Analyzer (Boehringer Mannheim
Diagnostics, Indianapolis, IN) for NHANES III, on a Hita-
chi 717 or 912 Analyzer (Roche Diagnostics, Indianapolis,
IN) for NHANES 2005–2006, and on a Roche Modular P
Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN)
for NHANES 2007–2008. Measurements of apolipoprotein
B for NHANES III were performed by using radial immu-
nodiffusion (Behring Diagnostics, Westwood, MA) and
rate immunonephelometrix assay (Beckman Instruments,
Brea, CA). Nephelometry was used to measure apolipopro-
tein B during 2005–2008 (NHANES 2005–2006: Dade
Behring BN100 nephelometer, Dade Behring, Deerfield, IL;
NHANES 2007–2008: ProSpec nephelometer, Dade
Behring GMBH, Marburg, Germany).
Participants could report up to 16 medications in
NHANES III and 20 medications in NHANES 2005–2008.
When prescription bottles were available, participants were
asked to show them to the interviewers. For our study, we
established the following two groups of medications:
cholesterol-lowering medications (statins [atorvastatin, flu-
vastatin, lovastatin, pravastatin, rosuvastatin, simvastatin],
ezetimibe, cholestyramine, probucol, colesevelam, and
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brate, gemfibrozil, and niacin). Products containing a
cholesterol-lowering medication in the form of a statin
and a triglyceride-lowering medication were counted as
one of each.
The following covariates were included in the analyses:
age, gender, race or ethnicity (whites, African Americans,
Mexican Americans, other), educational status (<high
school, high school graduate or equivalent, >high school),
and body mass index. Measured weight and height were
used to calculate and categorize body mass index levels
(<25, 25- < 30, and ≥30 kg/m2).
For participants with diagnosed diabetes, we also cal-
culated 10-year predicted cardiovascular risk using the
UK Prospective Diabetes Study (UKPDS) risk engine
that uses the following variables: age at diagnosis of dia-
betes, gender, race or ethnicity, smoking status, concen-
tration of HbA1c, systolic blood pressure, and ratio of
concentrations of total cholesterol to high-density lipo-
protein cholesterol [14]. Participants who had smoked at
least 100 cigarettes during their lifetime and were cur-
rently smoking were designated as current smokers. For
systolic blood pressure, we averaged the second and
third measurements of systolic blood pressure.
The analyses were limited to participants aged ≥20
years who attended the morning examination and had
fasted ≥8 hours. Pregnant women were excluded.
Adjusted mean concentrations of lipids and apolipopro-
tein B were calculated by using analysis of covariance.
Differences in percentages and means were tested by
using chi-square tests and t-tests, respectively. In
addition, changes in the prevalence of abnormal concen-
trations of lipids were examined by log-linear regression
analysis adjusting for age (continuous) and age, gender,
race or ethnicity, educational status, and body mass
index (continuous). Data management was done with
SAS and estimates were produced with SUDAAN to ac-
count for the complex sampling designs of the surveys.
Sample sizes reflect unweighted numbers, whereas sam-
pling weights were used to generate estimates.
Results
Of the 3840 participants aged ≥20 years in NHANES III
who attended the morning examination, 3510 were left
after excluding pregnant women and participants who
had fasted <8 hours. Additional exclusions of partici-
pants who had missing data for variables needed to es-
tablish glycemic status and for lipids reduced the sample
size to 3225 participants. After covariates with missing
values were excluded, 3202 were included in the analyses.
In NHANES 2005–2008, 4341 participants attended the
morning examination, 4173 remained after excluding preg-
nant women and participants who had fasted <8 hours,
4020 were left after excluding participants who had missingdata for variables needed to establish glycemic status and
for lipids, and 3949 were included in the analyses after
excluding participants who had covariates with missing
values. Changes in covariates by glycemic status are shown
in Table 1.
Among participants with diagnosed diabetes, undiag-
nosed diabetes, prediabetes, and normoglycemia, signifi-
cant decreases occurred in concentrations of total
cholesterol, low-density lipoprotein cholesterol, non-
high-density lipoprotein cholesterol, and apolipoprotein
B (Table 2). Concentrations of high-density lipoprotein
cholesterol also increased significantly among partici-
pants with prediabetes and normoglycemia in all models
and among participants with diagnosed diabetes in the
most adjusted model. Log-transformed concentrations of
triglycerides decreased significantly among participants
with undiagnosed diabetes and prediabetes only in the
most adjusted model.
A secondary observation of the results shown in
Table 2 was that participants with undiagnosed diabetes
and prediabetes exhibited worse lipid profiles than parti-
cipants with diagnosed diabetes. During 2005–2008,
unadjusted and adjusted concentrations of total choles-
terol, low-density lipoprotein cholesterol, non-high-
density lipoprotein cholesterol, and apolipoprotein B
were significantly higher among participants with un-
diagnosed diabetes and prediabetes than among partici-
pants with diagnosed diabetes.
To estimate the possible impact of improvements in con-
centrations of total cholesterol and high-density lipoprotein
cholesterol may have had on 10-year predicted risk from
cardiovascular disease, we estimated risk using the UKPDS
risk engine for the adults with diagnosed diabetes during
1988–1994 under two scenarios: 1) using the original data
and 2) after reducing the ratio of TC/HDLC by approxi-
mately 20% for each participant while holding the values
for the other variables that are part of the risk engine con-
stant. The 20% reduction represents the mean improve-
ment in the mean ratio of TC/HDLC from 1988–1994 to
2005–2008. The predicted 10-year risk dropped from
21.2% (95% confidence interval: 15.8—26.5) to 17.3% (95%
confidence interval: 12.7—21.9).
The unadjusted use of cholesterol-lowering medica-
tions increased significantly in all groups (P for all com-
parisons <0.001) and was particularly striking among
participants with diagnosed diabetes in whom the use
increased from approximately 1% to 49% (Figure 1). The
use of medications for lowering concentrations of trigly-
cerides or increasing concentrations of high-density lipo-
protein cholesterol also rose but at a less impressive
rate. The largest increases were noticed in participants
with diagnosed diabetes among whom the unadjusted per-
centage increased from about 2% to almost 8% (P = 0.011)
and in participants with undiagnosed diabetes among
Table 1 Unadjusted percentages, medians, or means (standard error) of selected sociodemographic and anthropometric characteristics among adults aged
> =20 years, National Health and Nutrition Examination Survey 1988–1991 and 2005-2008
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normal
1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P*
N 207 457 92 103 566 850 2337 2539
Age (years) - median 59.9 (1.6) 59.8 (1.1) — 58.6 (2.1) 61.6 (3.0) — 56.9 (2.2) 56.5 (0.9) — 38.0 (0.8) 40.9 (0.8) —
Age (%) 0.783 0.531 0.257 0.001
20-39 years 13.3 (4.3) 10.8 (1.7) 13.2 (4.8) 6.7 (3.0) 18.0 (2.7) 14.7 (1.4) 51.5 (1.6) 46.2 (1.4)
40-59 years 33.6 (4.8) 37.3 (2.6) 38.1 (6.5) 40.8 (6.2) 36.2 (3.3) 41.2 (1.9) 30.6 (1.5) 38.8 (1.4)
≥60 years 53.1 (3.8) 51.9 (2.9) 48.7 (6.6) 52.5 (6.5) 45.9 (4.3) 44.1 (2.1) 17.9 (1.5) 15.0 (1.4)
Men (%) 36.4 (5.7) 44.4 (3.0) 0.221 49.5 (7.9) 56.6 (6.1) 0.482 53.3 (3.1) 47.9 (2.3) 0.170 47.9 (1.3) 48.8 (1.0) 0.567
Race or ethnicity (%) 0.268 0.932 0.020 0.004
White 73.4 (4.3) 65.3 (4.3) 53.3 (6.3) 55.3 (6.9) 63.9 (5.0) 66.7 (3.4) 81.1 (2.2) 73.7 (2.0)
African American 15.1 (3.6) 17.3 (2.9) 29.8 (4.9) 28.3 (4.0) 24.0 (3.1) 17.4 (2.5) 7.7 (1.0) 8.3 (1.1)
Mexican American 8.4 (1.4) 8.2 (1.4) 8.1 (2.6) 9.9 (2.7) 4.8 (0.5) 7.3 (1.3) 4.7 (0.6) 8.0 (0.9)
Other 3.1 (2.2) 9.2 (2.3) 8.8 (5.9) 6.6 (3.1) 7.3 (2.4) 8.6 (1.9) 6.5 (1.7) 9.9 (1.1)
≥High school graduates (%) 57.4 (5.5) 70.4 (2.2) 0.030 50.2 (5.4) 71.7 (4.8) 0.013 60.3 (2.8) 77.7 (1.7) <0.001 79.4 (1.9) 84.4 (1.2) 0.034
Body mass index ≥30 kg/m2 (%) 38.2 (5.8) 61.7 (2.8) 0.001 60.3 (7.1) 68.4 (6.2) 0.378 28.2 (2.5) 43.0 (2.0) <0.001 17.4 (1.3) 27.5 (1.3) <0.001
Body mass index (kg/m2) 29.6 (0.7) 32.8 (0.5) 0.001 32.6 (1.8) 34.8 (1.3) 0.343 27.6 (0.3) 30.2 (0.3) <0.001 25.7 (0.2) 27.5 (0.2) <0.001
HbA1c (%) 6.8 (0.2) 7.2 (0.1) 0.060 7.8 (0.3) 7.5 (0.2) 0.345 5.9 (<0.1) 5.9 (<0.1) 0.024 5.0 (<0.1) 5.2 (<0.1) <0.001
















Table 2 Unadjusted and least-square adjusted mean concentrations (standard error) of lipids and apolipoprotein B among adults aged ≥20 years, by glycemic
status and survey, National Health and Nutrition Examination Surveys 1988–1991 and 2005-2006
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normal
1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P*
N 207 457 92 103 566 850 2337 2539
Unadjusted
Total cholesterol (mg/dl) 215.0 (3.6) 181.0 (2.3) <0.001 223.0 (5.0) 200.4 (4.8) 0.002 218.0 (1.7) 202.9 (1.8) <0.001 200.5 (1.4) 195.0 (0.9) 0.002
High-density lipoprotein cholesterol (mg/dl) 49.1 (1.6) 50.7 (1.0) 0.390 44.9 (1.8) 47.7 (1.6) 0.234 48.0 (0.7) 53.6 (0.7) <0.001 51.8 (0.7) 55.7 (0.4) <0.001
Low-density lipoprotein cholesterol (mg/dl) 135.4 (2.9) 100.5 (1.8) <0.001 143.3 (3.8) 121.7 (4.3) <0.001 142.6 (1.8) 122.3 (1.4) <0.001 124.8 (1.3) 115.4 (0.9) <0.001
Non-high-density lipoprotein cholesterol (mg/dl) 166.0 (4.4) 130.3 (2.0) <0.001 178.1 (4.6) 152.7 (4.4) <0.001 170.0 (1.8) 149.3 (1.8) <0.001 148.8 (1.5) 139.3 (1.0) <0.001
Triglycerides (mg/dl)† 153.1 (9.8) 148.9 (4.0) 0.687 173.6 (10.1) 155.4 (10.1) 0.207 137.0 (4.2) 136.9 (3.6) 0.985 119.6 (3.6) 119.5 (1.7) 0.974
Triglycerides (mg/dl)‡ 137.8 (9.7) 133.0 (3.6) 0.634 158.4 (9.2) 135.0 (9.4) 0.084 122.0 (3.5) 122.1 (2.9) 0.970 104.3 (3.2) 104.6 (1.6) 0.933
Apolipoprotein B (mg/dl) 114.2 (2.7) 96.3 (1.5) <0.001 120.3 (3.4) 110.4 (3.1) 0.035 115.6 (1.3) 106.2 (1.2) <0.001 102.0 (0.9) 98.6 (0.8) 0.011
Age-adjusted
Total cholesterol (mg/dl) 206.7 (3.5) 172.3 (2.5) <0.001 215.2 (4.5) 191.3 (4.7) 0.001 211.0 (1.7) 195.9 (1.8) <0.001 202.9 (1.4) 197.0 (0.8) <0.001
High-density lipoprotein cholesterol (mg/dl) 47.5 (1.6) 49.1 (1.0) 0.418 43.4 (1.7) 46.0 (1.6) 0.265 46.7 (0.7) 52.3 (0.7) <0.001 52.2 (0.7) 56.0 (0.4) <0.001
Low-density lipoprotein cholesterol (mg/dl) 130.2 (2.8) 95.1 (2.0) <0.001 138.5 (3.7) 116.0 (4.3) <0.001 138.3 (1.8) 118.0 (1.5) <0.001 126.3 (1.3) 116.7 (0.8) <0.001
Non-high-density lipoprotein cholesterol (mg/dl) 159.2 (4.3) 123.3 (2.2) <0.001 171.8 (4.3) 145.2 (4.3) <0.001 164.3 (1.9) 143.7 (1.8) <0.001 150.7 (1.5) 141.0 (0.9) <0.001
Triglycerides (mg/dl)† 145.1 (9.6) 140.5 (4.2) 0.662 166.1 (9.8) 146.6 (9.7) 0.160 130.2 (4.4) 130.1 (3.5) 0.993 121.9 (3.6) 121.5 (1.6) 0.912
Triglycerides (mg/dl)‡ 127.9 (8.9) 123.0 (3.6) 0.601 147.7 (8.3) 124.3 (8.3) 0.052 114.5 (3.3) 114.7 (2.5) 0.957 106.5 (3.2) 106.5 (1.5) 1.000
Apolipoprotein B (mg/dl) 109.9 (2.7) 91.9 (1.6) <0.001 116.3 (3.2) 105.7 (3.1) 0.024 112.0 (1.3) 102.6 (1.2) <0.001 103.2 (0.9) 99.7 (0.7) 0.006
Adjusted for age, gender, race or ethnicity,
education, and body mass index
Total cholesterol (mg/dl) 205.6 (3.3) 169.6 (2.5) <0.001 213.0 (4.7) 187.6 (4.3) <0.001 211.5 (1.8) 194.7 (1.9) <0.001 203.7 (1.3) 197.0 (0.8) <0.001
High-density lipoprotein cholesterol (mg/dl) 48.1 (1.2) 52.2 (1.0) 0.010 46.6 (2.0) 51.1 (2.1) 0.128 46.9 (0.7) 53.7 (0.7) <0.001 51.2 (0.6) 56.0 (0.3) <0.001
Low-density lipoprotein cholesterol (mg/dl) 129.2 (2.6) 91.8 (1.9) <0.001 135.1 (4.2) 110.6 (3.8) <0.001 138.0 (1.9) 116.3 (1.5) <0.001 127.4 (1.3) 116.8 (0.7) <0.001
Non-high-density lipoprotein cholesterol (mg/dl) 157.5 (3.9) 117.4 (2.2) <0.001 166.4 (5.3) 136.4 (3.7) <0.001 164.6 (1.9) 141.0 (1.9) <0.001 152.6 (1.3) 141.0 (0.8) <0.001
Triglycerides (mg/dl)† 141.7 (8.2) 128.2 (4.3) 0.153 156.3 (11.5) 129.6 (11.4) 0.100 133.0 (3.8) 125.2 (3.5) 0.137 125.9 (3.2) 120.9 (1.6) 0.161
Triglycerides (mg/dl)‡ 124.4 (7.2) 111.0 (3.3) 0.078 136.3 (10.0) 108.0 (8.6) 0.032 117.5 (2.7) 110.1 (2.3) 0.041 110.2 (2.9) 105.9 (1.4) 0.179
Apolipoprotein B (mg/dl) 108.7 (2.5) 88.0 (1.5) <0.001 112.5 (3.4) 99.7 (2.8) 0.005 111.8 (1.5) 100.8 (1.2) <0.001 104.4 (0.9) 99.8 (0.6) <0.001
































































































































































































































Figure 1 Percentages (95% confidence interval) of participants aged ≥20 years who reported using cholesterol-lowering medications
(panel A) and fenofibrate, gemfibrozil, or niacin (panel B), by survey period and glycemic status, National Health and Nutrition
Examination Survey 1988–1991 and 2005–2006. *Results were adjusted for age, gender, race or ethnicity, educational status, and body
mass index.
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5% (P = 0.147).
The analyses that generated the results shown in
Table 2 were repeated after excluding participants who
were using cholesterol-lowering medications, fenofibrate,
gemfibrozil, and niacin (Table 3). Many of the significant
improvements in lipid concentration persisted in ana-
lyses that excluded participants who used cholesterol-
lowering and triglyceride-lowering medications, although
the magnitude of the decrease narrowed to some degree
in many comparisons.
Changes in concentrations of lipids in dichotomized
form are presented in Table 4. In all four groups, elevated
concentrations of low-density lipoprotein cholesterol, non-
high-density lipoprotein cholesterol, and apolipoprotein Bdecreased significantly after adjustment for age, gender,
race or ethnicity, education, and body mass index. Among
persons with prediabetes and normoglycemia, low concen-
trations of high-density lipoprotein cholesterol decreased
significantly. A significant decrease in the prevalence of
the lipid triad consisting of low concentrations of high-
density lipoprotein cholesterol and elevated concentrations
of triglycerides and apolipoprotein B was noted among
participants with prediabetes and normoglycemia.
Correlation coefficients among concentrations of tri-
glycerides (log-transformed), non-high-density lipopro-
tein cholesterol, and apolipoprotein B are shown in
Table 5. The largest correlation coefficients were noted
for non-high-density lipoprotein cholesterol and apoli-
poprotein B and ranged from 0.90 to 0.95.
Table 3 Unadjusted and least-square adjusted mean concentrations (standard error) of lipids and apolipoprotein B among adults aged > =20 years,
by glycemic status and survey, National Health and Nutrition Examination Survey 1988–1991 and 2005–2006
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normal
1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P*
N 200 211 91 67 545 634 2302 2290
Unadjusted
Total cholesterol (mg/dl) 214.4 (3.7) 194.6 (3.2) <0.001 224.5 (5.0) 208.8 (6.0) 0.051 217.5 (1.7) 209.9 (2.2) 0.008 199.9 (1.3) 196.0 (1.2) 0.034
High-density lipoprotein cholesterol (mg/dl) 48.8 (1.6) 51.2 (1.5) 0.287 44.8 (1.8) 46.3 (2.0) 0.580 48.1 (0.7) 53.5 (0.9) <0.001 51.8 (0.7) 55.9 (0.5) <0.001
Low-density lipoprotein cholesterol (mg/dl) 134.7 (3.0) 113.8 (2.6) <0.001 144.8 (3.9) 130.0 (5.3) 0.028 142.2 (1.8) 129.8 (1.6) <0.001 124.3 (1.3) 116.7 (1.1) <0.001
Non-high-density lipoprotein cholesterol (mg/dl) 165.6 (4.6) 143.5 (3.2) <0.001 179.7 (4.5) 162.5 (5.5) 0.019 169.4 (1.8) 156.4 (2.1) <0.001 148.1 (1.5) 140.1 (1.2) <0.001
Triglycerides (mg/dl)† 154.5 (9.8) 148.1 (7.4) 0.604 174.0 (10.4) 163.2 (11.9) 0.496 135.9 (4.3) 135.8 (3.7) 0.987 118.8 (3.6) 116.9 (1.7) 0.639
Triglycerides (mg/dl)‡ 139.1 (9.9) 131.2 (7.1) 0.513 158.3 (9.6) 140.6 (12.1) 0.263 120.9 (3.7) 120.5 (3.0) 0.936 103.8 (3.2) 102.3 (1.6) 0.674
Apolipoprotein B (mg/dl) 113.8 (2.8) 103.2 (2.4) 0.005 121.7 (3.1) 116.9 (3.6) 0.321 115.1 (1.2) 109.6 (1.3) 0.003 101.6 (0.9) 98.7 (1.0) 0.041
Age-adjusted
Total cholesterol (mg/dl) 202.5 (3.7) 185.8 (3.6) 0.002 212.9 (4.4) 198.4 (6.3) 0.070 207.4 (1.8) 202.1 (2.0) 0.048 201.6 (1.2) 198.5 (1.1) 0.062
High-density lipoprotein cholesterol (mg/dl) 46.9 (1.6) 49.7 (1.5) 0.202 42.9 (1.8) 44.6 (2.0) 0.528 46.5 (0.7) 52.2 (0.9) <0.001 52.1 (0.7) 56.3 (0.4) <0.001
Low-density lipoprotein cholesterol (mg/dl) 126.6 (2.9) 107.8 (2.9) <0.001 137.0 (3.7) 122.9 (5.7) 0.046 135.3 (1.9) 124.5 (1.5) <0.001 125.5 (1.3) 118.4 (1.1) <0.001
Non-high-density lipoprotein cholesterol (mg/dl) 155.6 (4.5) 136.1 (3.6) 0.001 170.0 (4.1) 153.8 (5.7) 0.028 160.9 (2.0) 149.9 (2.0) <0.001 149.5 (1.4) 142.2 (1.2) <0.001
Triglycerides (mg/dl)† 145.2 (9.6) 141.2 (7.6) 0.743 164.9 (10.0) 155.0 (11.5) 0.518 127.9 (4.4) 129.7 (3.6) 0.755 120.2 (3.6) 118.9 (1.7) 0.750
Triglycerides (mg/dl)‡ 127.6 (9.0) 123.1 (6.9) 0.683 145.6 (8.5) 130.4 (11.0) 0.283 112.3 (3.4) 113.9 (2.6) 0.713 105.1 (3.2) 104.2 (1.6) 0.797
Apolipoprotein B (mg/dl) 107.8 (2.7) 98.7 (2.6) 0.019 115.8 (2.9) 111.6 (3.8) 0.388 109.9 (1.4) 105.7 (1.2) 0.018 102.4 (0.9) 100.0 (0.9) 0.066
Adjusted for age, gender, race or ethnicity,
education, and body mass index
Total cholesterol (mg/dl) 201.7 (3.5) 183.7 (3.4) <0.001 211.3 (4.7) 193.9 (6.2) 0.029 208.0 (1.9) 200.7 (2.1) 0.010 202.2 (1.2) 198.4 (1.0) 0.018
High-density lipoprotein cholesterol (mg/dl) 48.0 (1.2) 52.9 (1.4) 0.009 46.8 (2.1) 51.0 (2.5) 0.213 47.0 (0.7) 53.9 (0.8) <0.001 51.2 (0.6) 56.3 (0.4) <0.001
Low-density lipoprotein cholesterol (mg/dl) 125.6 (2.7) 104.8 (2.8) <0.001 133.7 (4.3) 116.3 (5.6) 0.016 135.0 (2.0) 122.5 (1.5) <0.001 126.2 (1.2) 118.5 (0.9) <0.001
Non-high-density lipoprotein cholesterol (mg/dl) 153.7 (4.0) 130.8 (3.4) <0.001 164.5 (5.3) 143.0 (5.9) 0.009 160.9 (2.0) 146.9 (2.0) <0.001 150.9 (1.2) 142.1 (0.9) <0.001
Triglycerides (mg/dl)† 140.6 (8.2) 129.7 (7.4) 0.324 154.1 (11.9) 134.0 (13.2) 0.258 129.6 (3.7) 124.4 (3.8) 0.319 123.4 (3.2) 118.1 (1.6) 0.141
Triglycerides (mg/dl)‡ 122.9 (7.3) 111.7 (6.0) 0.224 133.2 (10.3) 109.4 (10.4) 0.107 114.3 (2.7) 109.0 (2.5) 0.148 108.0 (2.8) 103.4 (1.4) 0.146
Apolipoprotein B (mg/dl) 106.4 (2.6) 95.0 (2.5) 0.002 111.8 (3.2) 104.2 (4.0) 0.148 109.6 (1.5) 103.5 (1.2) 0.002 103.4 (0.9) 100.0 (0.7) 0.006
Participants who reported using cholesterol-lowering medications, fenofibrate, gemfibrozil, and niacin were excluded.


















Table 4 Unadjusted and adjusted percentages (standard error) of lipids and apolipoprotein B among adults aged ≥20 years, by glycemic status and survey,
National Health and Nutrition Examination Surveys 1988–1991 and 2005-2006
Diagnosed diabetes Undiagnosed diabetes Prediabetes Normal
1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P* 1988-1991 2005-2008 P*
N 207 457 92 103 566 850 2337 2539
Unadjusted
High-density lipoprotein cholesterol <40 mg/dl in men,
<50 mg/dl in women
46.4 (5.8) 37.2 (3.0) 0.165 57.5 (8.7) 34.4 (6.4) 0.037 41.8 (2.8) 24.9 (1.7) <0.001 33.3 (1.7) 22.4 (1.1) <0.001
High-density lipoprotein cholesterol <40 mg/dl in men,
<50 mg/dl in women or medication use†
47.9 (5.8) 40.7 (3.0) 0.275 57.5 (8.7) 37.5 (6.5) 0.071 43.4 (3.1) 26.4 (1.6) <0.001 33.6 (1.6) 23.0 (1.0) <0.001
Low-density lipoprotein cholesterol ≥100 mg/dl 86.1 (4.7) 42.9 (2.6) <0.001 91.5 (3.3) 70.3 (4.9) 0.001 90.0 (1.4) 75.0 (1.7) <0.001 74.4 (1.8) 66.0 (1.2) <0.001
Low-density lipoprotein cholesterol ≥100 mg/dl or
medication use
86.1 (4.7) 79.1 (2.4) 0.183 94.4 (2.4) 87.0 (4.9) 0.180 90.1 (1.4) 88.4 (1.3) 0.365 74.4 (1.8) 70.6 (1.2) 0.085
Non-high-density lipoprotein cholesterol ≥130 mg/dl 81.9 (5.5) 43.6 (2.8) <0.001 91.7 (3.4) 67.5 (5.4) <0.001 85.0 (1.5) 67.9 (1.9) <0.001 65.2 (1.7) 57.8 (0.8) <0.001
Triglycerides ≥150 mg/dl 44.7 (7.0) 43.9 (2.7) 0.909 54.3 (5.8) 43.0 (6.9) 0.215 33.9 (1.9) 33.2 (2.1) 0.797 24.7 (2.3) 24.7 (1.1) 0.997
Triglycerides ≥150 mg/dl or medication use† 46.9 (6.9) 47.8 (3.0) 0.905 54.3 (5.8) 44.1 (7.1) 0.271 35.9 (1.9) 34.6 (2.0) 0.625 24.9 (2.3) 25.1 (1.0) 0.936
Triglycerides ≥150 mg/dl or use of TG-lowering or
cholesterol-lowering medications‡
47.6 (6.7) 73.5 (2.9) 0.001 54.3 (5.8) 67.4 (5.9) 0.121 36.9 (2.0) 50.2 (2.1) <0.001 25.3 (2.4) 30.3 (1.3) 0.070
Apolipoprotein B ≥80 mg/dl 91.1 (3.6) 72.8 (2.1) <0.001 95.8 (2.8) 87.9 (4.2) 0.123 92.8 (1.3) 86.6 (1.4) 0.002 81.7 (1.3) 77.2 (1.0) 0.007
Lipid triad: definition 1§ 31.4 (6.5) 21.6 (2.8) 0.172 35.7 (7.7) 23.4 (5.2) 0.190 20.7 (1.7) 13.8 (1.2) 0.002 13.1 (1.5) 9.8 (0.7) 0.050
Lipid triad: definition 2ǁ 33.3 (6.4) 24.8 (2.7) 0.228 35.7 (7.7) 24.0 (5.3) 0.212 23.3 (1.9) 15.2 (1.1) 0.001 13.5 (1.4) 10.4 (0.7) 0.056
Lipid triad: definition 3¶ 33.3 (6.4) 26.6 (2.8) 0.342 35.7 (7.7) 25.4 (5.8) 0.287 23.8 (2.1) 16.1 (1.1) 0.002 13.7 (1.5) 10.9 (0.7) 0.102
Age-adjusted
High-density lipoprotein cholesterol <40 mg/dl in men,
<50 mg/dl in women
51.5 (6.8) 41.5 (3.3) 0.180 63.4 (9.5) 38.7 (7.4) 0.042 45.6 (3.0) 27.2 (1.9) <0.001 32.4 (1.6) 21.9 (1.0) <0.001
High-density lipoprotein cholesterol <40 mg/dl in men,
<50 mg/dl in women or medication use†
52.1 (6.7) 44.5 (3.3) 0.293 62.2 (9.3) 41.2 (7.3) 0.078 46.6 (3.4) 28.3 (1.8) <0.001 32.8 (1.6) 22.5 (1.0) <0.001
Low-density lipoprotein cholesterol ≥100 mg/dl 80.9 (4.4) 40.2 (2.4) <0.001 86.2 (3.3) 65.5 (4.6) 0.001 85.2 (1.4) 71.1 (1.7) <0.001 75.8 (1.7) 67.1 (1.2) <0.001
Low-density lipoprotein cholesterol ≥100 mg/dl or
medication use
78.1 (4.2) 71.4 (2.2) 0.154 86.1 (2.7) 78.1 (4.3) 0.127 82.8 (1.3) 81.4 (1.4) 0.386 76.6 (1.7) 72.5 (1.2) 0.062
Non-high-density lipoprotein cholesterol ≥130 mg/dl 74.2 (5.1) 39.3 (2.6) <0.001 83.6 (3.7) 60.5 (4.8) <0.001 78.0 (1.6) 62.5 (1.9) <0.001 67.1 (1.6) 59.4 (0.8) <0.001
Triglycerides ≥150 mg/dl 38.6 (6.1) 37.7 (2.6) 0.882 47.4 (4.7) 36.6 (5.8) 0.155 29.8 (2.0) 29.3 (1.9) 0.832 25.8 (2.4) 25.7 (1.1) 0.970
Triglycerides ≥150 mg/dl or medication use† 40.1 (5.9) 40.6 (2.8) 0.936 46.9 (4.7) 37.2 (5.9) 0.198 31.4 (1.8) 30.3 (1.8) 0.649 26.2 (2.3) 26.3 (1.0) 0.970
Triglycerides ≥150 mg/dl or use of TG-lowering or
cholesterol-lowering medications‡
















Table 4 Unadjusted and adjusted percentages (standard error) of lipids and apolipoprotein B among adults aged ≥20 years, by glycemic status and survey,
National Health and Nutrition Examination Surveys 1988–1991 and 2005-2006 (Continued)
Apolipoprotein B ≥80 mg/dl 85.4 (3.2) 68.1 (2.1) <0.001 90.2 (2.9) 81.9 (4.0) 0.096 87.8 (1.3) 82.0 (1.4) 0.001 83.3 (1.3) 78.5 (0.9) 0.005
Lipid triad: definition 1§ 30.0 (6.4) 20.6 (2.8) 0.174 34.3 (7.2) 22.3 (5.1) 0.179 20.0 (1.8) 13.3 (1.1) 0.002 13.3 (1.5) 9.9 (0.7) 0.048
Lipid triad: definition 2ǁ 30.9 (6.2) 22.9 (2.6) 0.226 33.3 (6.9) 22.0 (4.9) 0.194 21.8 (1.8) 14.2 (1.1) <0.001 13.8 (1.4) 10.6 (0.7) 0.053
Lipid triad: definition 3¶ 30.5 (6.1) 24.2 (2.7) 0.336 32.9 (6.9) 23.0 (5.3) 0.262 22.0 (2.0) 14.9 (1.1) 0.002 14.0 (1.5) 11.2 (0.7) 0.098
Adjusted for age, gender, race or ethnicity, education,
and body mass index
High-density lipoprotein cholesterol <40 mg/dl in men,
<50 mg/dl in women
45.8 (5.7) 34.8 (3.0) 0.073 50.6 (10.4) 31.0 (7.0) 0.111 47.6 (2.9) 25.6 (1.8) <0.001 34.0 (1.8) 21.9 (1.1) <0.001
High-density lipoprotein cholesterol <40 mg/dl in men,
<50 mg/dl in women or medication use†
46.7 (5.6) 37.6 (3.1) 0.131 50.3 (10.0) 33.3 (7.1) 0.157 48.6 (3.2) 26.7 (1.7) <0.001 34.4 (1.7) 22.5 (1.0) <0.001
Low-density lipoprotein cholesterol ≥100 mg/dl 79.8 (4.1) 38.1 (2.3) <0.001 82.2 (3.1) 60.3 (3.8) <0.001 85.6 (1.7) 69.2 (1.9) <0.001 77.4 (1.8) 67.0 (1.2) <0.001
Low-density lipoprotein cholesterol ≥100 mg/dl or
medication use
77.6 (3.9) 67.8 (2.2) 0.024 82.8 (2.6) 71.8 (4.0) 0.018 83.6 (1.6) 79.3 (1.6) 0.018 78.1 (1.8) 72.4 (1.2) 0.012
Non-high-density lipoprotein cholesterol ≥130 mg/dl 72.1 (4.5) 35.6 (2.4) <0.001 76.6 (4.0) 51.9 (3.9) <0.001 79.2 (1.9) 59.7 (2.0) <0.001 69.8 (1.6) 59.3 (0.8) <0.001
Triglycerides ≥150 mg/dl 36.9 (5.3) 32.6 (2.4) 0.444 41.5 (7.2) 29.2 (6.0) 0.183 31.8 (1.9) 27.7 (1.9) 0.090 27.6 (2.4) 25.3 (1.0) 0.376
Triglycerides ≥150 mg/dl or medication use† 38.4 (5.1) 35.3 (2.6) 0.558 41.3 (7.1) 29.8 (6.1) 0.209 33.4 (1.6) 28.7 (1.7) 0.025 28.0 (2.4) 25.8 (0.9) 0.399
Triglycerides ≥150 mg/dl or use of TG-lowering or
cholesterol-lowering medications‡
37.0 (4.9) 51.2 (2.8) 0.009 40.1 (5.7) 42.9 (5.2) 0.707 32.0 (1.8) 39.4 (1.8) 0.001 28.9 (2.5) 32.0 (1.2) 0.255
Apolipoprotein B ≥80 mg/dl 84.1 (3.1) 64.5 (2.0) <0.001 85.8 (3.1) 75.5 (3.4) 0.017 88.2 (1.6) 80.0 (1.5) <0.001 84.9 (1.2) 78.5 (0.9) <0.001
Lipid triad: definition 1§ 27.6 (5.6) 17.7 (2.5) 0.099 28.4 (8.0) 17.6 (5.0) 0.240 21.7 (1.8) 12.7 (1.1) <0.001 14.1 (1.5) 9.8 (0.7) 0.013
Lipid triad: definition 2ǁ 28.7 (5.5) 19.7 (2.4) 0.117 28.2 (7.6) 17.5 (4.9) 0.227 23.7 (1.8) 13.6 (1.0) <0.001 14.7 (1.5) 10.4 (0.7) 0.012
Lipid triad: definition 3 28.3 (5.4) 20.8 (2.4) 0.186 27.9 (7.3) 18.1 (5.0) 0.260 23.7 (1.9) 14.1 (1.0) <0.001 14.9 (1.5) 11.1 (0.7) 0.028
*P-values for difference of predicted marginal from log-linear regressions.
†Use of fenofibrate, gemfibrozil, and niacin.
‡Use of cholesterol-lowering medications as well as fenofibrate, gemfibrozil, and niacin.
§Definition 1 was based on measured values of concentrations of high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B.
ǁ Definition 2: use of fenofibrate, gemfibrozil, and niacin was counted as having elevated concentrations of triglycerides and decreased concentrations of high-density lipoprotein cholesterol.
¶Definition 3: use of cholesterol-lowering medications, fenofibrate, gemfibrozil, and niacin was counted as having elevated concentrations of triglycerides and use of fenofibrate, gemfibrozil, and niacin was counted as
















Table 5 Unadjusted Pearson correlation coefficients
among triglycerides, non-high-density lipoprotein
cholesterol, and apolipoprotein B among adults aged
> =20 years, National Health and Nutrition Examination
Survey 2005-2008






Diagnosed diabetes 0.40 0.40 0.96
Undiagnosed diabetes 0.45 0.37 0.95
Prediabetes 0.51 0.45 0.90
Normal 0.51 0.49 0.95
apo B = apolipoprotein B; non-HDLC = non-high-density lipoprotein
cholesterol; TG = triglycerides.
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Several key points emerged from our analyses. First, the
lipid profile of adults with undiagnosed diabetes during
1988–1991 was the worst of the four groups; these parti-
cipants had the lowest adjusted mean concentration of
high-density lipoprotein cholesterol or the highest
adjusted mean concentrations of total cholesterol, non-
high-density lipoprotein cholesterol, triglycerides, and
apolipoprotein B. By 2005–2008, however, this group no
longer uniformly had the worst mean concentrations of
lipids and apolipoprotein B. Second, unadjusted and
adjusted mean concentrations of several lipids improved
from 1988–1991 to 2005–2008 among adults in all four
groups. Third, some of this improvement was likely a con-
sequence of the increased use of cholesterol-lowering
medications and, to a lesser degree, the increased use of
triglyceride-lowering medications. Fourth, the age-adjusted
prevalence of the atherogenic lipid triad, as we defined it,
decreased significantly only among adults with prediabetes
and normoglycemia.
Adults with diabetes experienced the largest absolute
decreases in mean concentrations of total cholesterol,
low-density lipoprotein cholesterol, non-high-density
lipoprotein cholesterol, and apolipoprotein B. All of
these lipids have been shown to be directly related to
the risk for cardiovascular disease, although a long-
running debate about the superiority of one lipid param-
eter over another in predicting risk of cardiovascular
disease remains unresolved [15-19]. Thus, the improve-
ment in all of these lipid parameters is encouraging and
suggests that the risk for cardiovascular disease, at least
from lipids, has declined over time. Previous studies
have shown that morbidity and mortality from cardio-
vascular disease among adults with diabetes have
declined in the United States [20,21].
The rapidly increasing use of cholesterol-lowering medi-
cations is undoubtedly a major contributor to the im-
provements in these lipids. The increased use of such
medications among adults with diabetes has been reported
previously [9]. The contribution of other factors is lessclear. The intake of dietary fat in the United States has not
changed appreciably in recent decades [22], and, thus, it
seems unlikely that changes in the intake of this macronu-
trient provide a ready explanation for the observed reduc-
tion in mean concentrations of these lipids. One factor that
should have worked against favorable improvements in
lipid concentrations is the strong increase in body mass
index; increased body mass index generally correlates with
increased concentrations of low-density lipoprotein choles-
terol, non-high-density lipoprotein cholesterol, apolipopro-
tein B, and triglycerides as well as decreased concentrations
of high-density lipoprotein cholesterol. The fact that
improvements in concentrations of various lipids were
observed in the face of the rising prevalence of obesity
testifies to the presence of other powerful secular trends
that were able to offset the potentially deleterious impact
of obesity on lipid concentrations.
In contrast, the mean concentrations of triglycerides
did not change significantly among patients with
diabetes. The mean concentration of high-density lipo-
protein cholesterol increased significantly only when
covariates including body mass index were taken into
account. Although the use of medications known to in-
fluence concentrations of these lipids increased signifi-
cantly, especially among adults with diagnosed diabetes,
the use of these agents is far less common than that of
cholesterol-lowering medications. Hence, the use of
fenofibrate, gemfibrozil, and niacin is unlikely to have
substantially influenced the observed mean concentra-
tions. Dietary practices can affect concentrations of tri-
glycerides. However, the intake of fat has changed little
since 1999–2000 whereas the intake of carbohydrates
has decreased [22]. Concentrations of high-density lipo-
protein cholesterol are influenced by physical activity, al-
cohol use, and other factors. Trends in physical activity
in the United States remain clouded because of incon-
sistency in recording physical activity in national sur-
veys. Data from the National Health Interview Survey
from 1999 to 2010 shows that some improvement in the
percentage of adults meeting current guidelines has
taken place [23]. A recent analysis of energy expenditure
in the workplace concluded that a reduction in energy
expenditure has occurred over five decades [24]. Per
capita alcohol consumption has increased slightly from a
little over 2.1 gallons during 1997–1998 to about 2.3
gallons during 2009 [25].
Among people with diabetes, changes in glycemic con-
trol can also affect lipid parameters. For example, in a
study of 73 patients with type 2 diabetes, improved gly-
cemic control was associated with favorable changes in
high-density lipoprotein cholesterol, apolipoprotein A1
and the ratio of apolipoprotein A1 to apolipoprotein B
[26]. Because data indicate that glycemic control has
improved in the United States [10,27], this development
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people with diabetes.
An interesting observation from our analyses is that
adults with undiagnosed diabetes and prediabetes
showed evidence of having worse lipid profiles than
adults with diagnosed diabetes. The high uptake of
cholesterol-lowering medications by adults with diag-
nosed diabetes likely improved the lipid profile of these
adults in comparison with the lipid profiles of adults
with undiagnosed diabetes and prediabetes. Neverthe-
less, mean concentrations of lipids generally changed
in a favorable direction among adults with undiag-
nosed diabetes and prediabetes, although the magni-
tude of the change was generally smaller than that
achieved by adults with diagnosed diabetes. This ob-
servation suggests that adults with undiagnosed dia-
betes and prediabetes are at increased cardiovascular
risk from uncontrolled lipid abnormalities and that,
once diabetes is diagnosed, adults with previously un-
diagnosed diabetes will benefit from treatment to
manage dyslipidemias.
Apolipoprotein B is the protein that constitutes the
principal structural element of lipoprotein particles for
very-low-density lipoprotein (VLDL), intermediate-
density lipoprotein (IDL), and LDL. Two forms of apoli-
poprotein B have been identified: apolipoprotein B48
and apolipoprotein B100. The latter is generally mea-
sured in assays of apolipoprotein B such as the present
study. Apolipoprotein B100 is produced in the liver,
incorporated into VLDL particles, and subsequently
secreted into the circulation where the particle is trans-
formed into LDL. Because there is one molecule of apo-
lipoprotein B per lipoprotein particle, concentrations of
apolipoprotein B reflect the number of VLDL, IDL, and
LDL particles. Apolipoprotein B is recognized by cell
receptors, leading to the uptake of the lipoprotein par-
ticle. Numerous studies have shown that concentrations
of apolipoprotein B are directly related to cardiovascular
risk, and some have argued that apolipoprotein B is a
better lipid measure for assessing cardiovascular risk
than are other lipid parameters such as low-density lipo-
protein cholesterol and non-high-density lipoprotein
cholesterol [15,17,18] although considerable disagree-
ment persists [16,19]. Because apolipoprotein B is not
routinely measured in clinical practice at present, alter-
native methods to derive estimates of concentrations of
apolipoprotein B have been pursued [28].
In persons with diabetes, a limited number of studies
has shown that concentrations of apolipoprotein B pre-
dict cardiovascular morbidity and mortality [29-32], but
not always better than other lipid markers [32]. Concen-
trations of apolipoprotein B have also been shown to be
associated with diabetic retinopathy [33], microalbu-
miuria [34,35], carotid atherosclerosis [36,37], andcoronary artery calcification [38]. Thus, the drop in
mean concentration of apolipoprotein B in adults with
diabetes in the present study, which was consistent with
the decreases in mean concentrations of low-density
lipoprotein cholesterol and non-high-density lipoprotein
cholesterol, suggests a lessening of cardiovascular risk
among people with diabetes. The data suggest that the
use of lipid-lowering medications accounted for a sub-
stantial portion of the decrease.
Current guidelines from the American Diabetes Asso-
ciation and the American College of Cardiology Founda-
tion call for reducing concentrations of apolipoprotein B
to less than 80 mg/dl in people who have diabetes in
addition to at least one additional major risk factor for
cardiovascular disease [39]. Elevated concentrations of
apolipoprotein B were the most pronounced dyslipide-
mia among all four groups of adults. Pharmacologic
approaches to accomplishing this goal in people with
diabetes rely mostly on the use of statins [40]. Insulin
treatment in patients with type 2 diabetes has been
shown to lower concentrations of apolipoprotein B [41].
Potential nonpharmacological approaches includes in-
creased physical activity and dietary change.
The findings of the present study are subject to several
limitations. First, methods and laboratories used to con-
duct the lipid measurements changed during the study
period. Although strict quality control procedures were
implemented in all surveys, direct comparisons were not
done. Supportive of the validity of our observations,
however, is that the changes in all the atherogenic
indices- low-density lipoprotein cholesterol, non-high-
density lipoprotein cholesterol, and apolipoprotein B-
were similar. Second, the sample sizes for some of
the groups, particularly diagnosed diabetes and un-
diagnosed diabetes, were small resulting in limited
statistical power to detect significant changes in lipid
concentrations. The available sample sizes also precluded
us from performing stratified analyses by various sociode-
mographic or other variables.
In conclusion, mean concentrations of several lipids and
apolipoprotein B decreased significantly from 1988–1991
to 2005–2008 among adults with diagnosed diabetes.
However, no statistically significant changes in concentra-
tions of triglycerides transpired. The rapid increase in the
use of lipid-lowering medications, especially among adults
with diagnosed diabetes, likely was a factor in the
observed changes. Despite these improvements, sizeable
percentages of adults with diabetes continue to have ele-
vated concentrations of low-density lipoprotein choles-
terol, triglycerides, and especially apolipoprotein B. Thus,
further progress in adequately managing dyslipidemias
in adults with diabetes, and thereby lessening their
risk for cardiovascular morbidity and mortality, remains
to be achieved.
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